<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03950882</url>
  </required_header>
  <id_info>
    <org_study_id>PXL770-003</org_study_id>
    <nct_id>NCT03950882</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Pharmacokinetics of PXL770 After 4 Weeks of Treatment in Subjects With NAFLD</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study to Assess the Pharmacokinetics of PXL770 After 4 Weeks of Treatment in Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poxel SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poxel SA</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the pharmacokinetics of PXL770 after 4 weeks of treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be performed in subjects with Nonalcoholic Fatty Liver Disease. The primary&#xD;
      endpoint will be the assessment of PXL770 exposure in plasma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Actual">March 31, 2020</completion_date>
  <primary_completion_date type="Actual">March 29, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK parameters of PXL770</measure>
    <time_frame>Day 26</time_frame>
    <description>AUC : Area under the plasma concentration curve</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters of PXL770</measure>
    <time_frame>Day 26</time_frame>
    <description>Minimum plasma concentration (Cmin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters of PXL770</measure>
    <time_frame>Day 26</time_frame>
    <description>Average plasma concentration (Cavg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters of PXL770</measure>
    <time_frame>Day 26</time_frame>
    <description>Time to maximum plasma concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters of PXL770</measure>
    <time_frame>Day 26</time_frame>
    <description>Apparent volume of distribution (Vz/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters of PXL770</measure>
    <time_frame>Day 26</time_frame>
    <description>Apparent oral drug clearance at steady state (CLss/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters of PXL770</measure>
    <time_frame>Day 26</time_frame>
    <description>Elimination rate constant (λz)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters of PXL770</measure>
    <time_frame>Day 26</time_frame>
    <description>Terminal elimination half-life (t½)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters of PXL770</measure>
    <time_frame>Day 26</time_frame>
    <description>Area under the concentration-time curve from time 0 to last observed concentration (AUClast)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters of PXL770</measure>
    <time_frame>Day 14 and Day 26</time_frame>
    <description>Food effect: Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters of PXL770</measure>
    <time_frame>Day 14 and Day 26</time_frame>
    <description>Food effect: AUCtau</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters of PXL770</measure>
    <time_frame>Day 14 and Day 26</time_frame>
    <description>Food effect: Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters of PXL770</measure>
    <time_frame>Day 27</time_frame>
    <description>PK profile during OGTT: AUCtau</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters of PXL770</measure>
    <time_frame>Day 27</time_frame>
    <description>PK profile during OGTT: Cmax</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Nonalcoholic Fatty Liver</condition>
  <arm_group>
    <arm_group_label>PXL770</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PXL770 500 mg once daily (QD) for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo once daily (QD) for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PXL770</intervention_name>
    <description>Oral capsule</description>
    <arm_group_label>PXL770</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral capsule</description>
    <arm_group_label>PXL770</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects have given written informed consent&#xD;
&#xD;
          -  Body mass index (BMI): ≥ 25 kg/m²&#xD;
&#xD;
          -  Hepatic steatosis (CAP ≥ 300)&#xD;
&#xD;
          -  Insulin-resistant but not diabetic subjects&#xD;
&#xD;
          -  Fasting plasma glucose &lt;126 mg/dL&#xD;
&#xD;
          -  Glomerular filtration rate (eGFR) ≥ 60 mL/[min*1.73 m²]&#xD;
&#xD;
          -  Alanine amino transferase (ALT) &gt; 20 IU/L in females and &gt; 30 IU/L in males&#xD;
&#xD;
          -  Effective contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of another form of liver disease&#xD;
&#xD;
          -  Evidence of liver cirrhosis&#xD;
&#xD;
          -  Evidence of hepatic impairment&#xD;
&#xD;
          -  Positive serologic evidence of current infectious liver disease&#xD;
&#xD;
          -  History of excessive alcohol intake&#xD;
&#xD;
          -  Acute cardiovascular disease with 24 weeks prior to screening&#xD;
&#xD;
          -  Uncontrolled high blood pressure&#xD;
&#xD;
          -  Any disease which in the Investigator's opinion which in the Investigator's opinion&#xD;
             would exclude the patient from the study&#xD;
&#xD;
          -  Use of non-permitted concomitant medication&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>High Point Clinical Trials Center</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 13, 2019</study_first_submitted>
  <study_first_submitted_qc>May 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2019</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

